BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23371019)

  • 1. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
    Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
    Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.
    Puig-Butille JA; Escámez MJ; Garcia-Garcia F; Tell-Marti G; Fabra À; Martínez-Santamaría L; Badenas C; Aguilera P; Pevida M; Dopazo J; del Río M; Puig S
    Oncotarget; 2014 Mar; 5(6):1439-51. PubMed ID: 24742402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
    Sherburn TE; Gale JM; Ley RD
    DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UVB-induced decrease of p16/CDKN2A expression in skin cancer patients.
    Krähn G; Leiter U; Udart M; Kaskel P; Peter RU
    Pigment Cell Res; 2001 Jun; 14(3):201-5. PubMed ID: 11434568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal assessment of the nevus phenotype in a melanoma kindred.
    Florell SR; Meyer LJ; Boucher KM; Porter-Gill PA; Hart M; Erickson J; Cannon-Albright LA; Pershing LK; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2004 Sep; 123(3):576-82. PubMed ID: 15304099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
    Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
    BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
    Jenkins NC; Jung J; Liu T; Wilde M; Holmen SL; Grossman D
    J Invest Dermatol; 2013 Apr; 133(4):1043-51. PubMed ID: 23190892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
    Shannon JA; Matias C; Luxford C; Kefford RF; Mann GJ
    Melanoma Res; 1999 Apr; 9(2):133-7. PubMed ID: 10380935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
    Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional reassessment of P16 variants using a transfection-based assay.
    Walker GJ; Gabrielli BG; Castellano M; Hayward NK
    Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
    Ming Z; Lim SY; Rizos H
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF.
    Sarkar-Agrawal P; Vergilis I; Sharpless NE; DePinho RA; Rünger TM
    J Natl Cancer Inst; 2004 Dec; 96(23):1790-3. PubMed ID: 15572761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
    Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
    Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.